1144080-27-2

Basic information

• Product Name: tert-butyl 2-(1,4-dioxaspiro[4.5]decan-8-yl)hydrazinecarboxylate
• Synonyms: tert-butyl 2-(1,4-dioxaspiro[4.5]decan-8-yl)hydrazinecarboxylate;Hydrazinecarboxylic acid, 2-(1,4-dioxaspiro[4.5]dec-8-yl)-, 1,1-dimethylethyl ester
• CAS NO: 1144080-27-2
• Molecular Formula: C13H24N2O4
• Molecular Weight: 272.34066
• Mol File: 1144080-27-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 2-(1,4-dioxaspiro[4.5]decan-8-yl)hydrazinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-(1,4-dioxaspiro[4.5]decan-8-yl)hydrazinecarboxylate(1144080-27-2)
• EPA Substance Registry System: tert-butyl 2-(1,4-dioxaspiro[4.5]decan-8-yl)hydrazinecarboxylate(1144080-27-2)

Safety Data

• Hazardous Substances Data: 1144080-27-2(Hazardous Substances Data)

Usage

General Description

Tert-butyl 2-(1,4-dioxaspiro[4.5]decan-8-yl)hydrazinecarboxylate is a chemical compound with a complex and specific molecular structure. It is a hydrazine derivative with a tert-butyl ester group and a carboxylate functional group. The compound is likely to have applications in organic synthesis and medicinal chemistry, given its unique structure and potential reactivity. It may also have potential as a building block for the synthesis of more complex molecules and pharmaceuticals. Its precise properties and potential uses would need to be determined through further research and experimentation.

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 870-46-2 t-butoxycarbonylhydrazine 

Downstream Products

• 1144080-29-4 1,4-dioxaspiro[4.5]decan-8-ylhydrazine 

Relevant articles and documents

PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.

Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 1-substituent

A series of pyrazolopyrimidine mammalian Target Of Rapamycin (mTOR) inhibitors with various substituents at the 1-position have been prepared, resulting in compounds with excellent potency, selectivity and microsomal stability. Combination of a 1-cyclohexyl ketal group with a 2,6-ethylene bridged morpholine in the 4-position and a ureidophenyl group in the 6-positon resulted in compound 8a, that selectively suppressed key mTOR biomarkers in vivo for at least 8 h following iv administration and showed excellent oral activity in a xenograft tumor model.